1. Introduction {#sec1}
===============

Liver fibrosis is a common pathological feature of chronic liver disease and a main contributor in the development of cirrhosis caused by chronic liver injury \[[@B1], [@B2]\]. It is characterized by excessive deposition of collagen-based extracellular matrix (ECM) in the liver and abnormal liver function. Various chemical/microbial factors could contribute to the occurrence of hepatic fibrosis, including alcohol, virus, drugs, toxicants, and autoimmune process \[[@B3]--[@B6]\]. Previous studies \[[@B7], [@B8]\] indicated that liver fibrosis, especially in early stage, could be reversed, while once the liver fibrosis develops into cirrhosis stage, it could not. Thereby, more and more scholars are working to find novel drugs that can effectively reverse or delay the development of hepatic fibrosis.

Since the 1970s, the traditional Chinese medicine(TCM) have been used for the treatment of liver fibrosis. Cumulating data have shown that the TCM compound possesses obvious advantages in treatment of liver fibrosis. However, due to the multicomponent, multitarget, and multichannel characteristics of TCM and their complex formulations, the detailed medicinal ingredients of Chinese medicines and their complex models of action are unclear, which impeded the modernization and clinical application of TCM \[[@B9]--[@B11]\]. In recent years, network pharmacology based on systems biology and polypharmacology is emerging. Network pharmacology explores the relevance of drug-disease from a holistic and systematic perspective, emphasizes the transition of research mode from "single target" to "multiple targets," and systematically expounds the principles and rules of interaction between organism and drugs. As a powerful tool for exploring the potential mechanisms of various actions of TCM formulas and novel active ingredients via constructing a network of interactions between drugs and genes, targets and diseases, it has been widely used in TCM research and became a new approach for the development of TCM \[[@B10]--[@B13]\].

Danshiliuhao Granule (DSLHG, composed of*Lysimachiae Herba*(LH),*Polygoni Cuspidati Rhizoma Et Radix*(PC),*Radix et Rhizoma Rhei*(RR),*Gardeniae Fructus*(GF),*Aurantii Fructus*(AF),*Aucklandiae Radix*(AR),*Corydalis Rhizoma*(CR), and Sodium Sulfate(SS)) is a Chinese herb preparation based on TCM prescription with wonderful anti-liver fibrosis effect and preservation of liver function. Our work provided theoretical basis for the registration of pharmaceutical preparations and laid the foundation for the subsequent acquisition of new medicine certificates. Among these herbal medicines, RR is a commonly used TCM. Many studies have proven that emodin has good clinical value in the treatment of liver fibrosis \[[@B14]--[@B16]\]. The rhein possesses anti-inflammatory and free radical scavenging effects and antifibrosis effect, protects liver cells, and reduces liver damage \[[@B17]\]. Additionally, PC exerts antibacterial, antiviral, and liver protection effect that can promote liver cell regeneration and recovery. Thereby, the beneficial effects of PC make it have therapeutic effect on acute hepatic ischemic injury, as evidenced by abrogated acute liver injury caused by carbon tetrachloride (CCl~4~) \[[@B18], [@B19]\]. In our study, we found that DSLHG could alleviate liver fibrosis induced by CCl~4~ in rats and raised one new hopeful drug for the treatment of hepatic fibrosis. However, due to its complex components and molecular mechanisms against liver fibrosis, which have not been fully elucidated, it is of great significance to explore the anti-liver fibrosis mechanisms of DSLHG through network pharmacology.

In this work, we investigated the pharmacological mechanisms by which DSLHG regulates liver fibrosis. For this purpose, we established and analyzed active compound-target(C-T)network. First of all, we selected the active ingredients according to pharmacokinetic parameters (oral bioavailability and drug-likeness) from public database and searched the potential targets of these compounds by PharmMapper server. Furthermore, we built a network of interactions among active components regarding their related-targets and target genes of liver fibrosis. Moreover, we conducted GO function analysis and relevant pathway enrichment analysis for the potential core targets of DSLHG acting on targeted disease. The schematic illustration of this study is shown in [Figure 1](#fig1){ref-type="fig"}.

2. Materials and Methods {#sec2}
========================

2.1. Reagents and Chemicals {#sec2.1}
---------------------------

Silibinin capsules were provided by Tianjin TASLY SANTS Pharmaceutical CO., Ltd. (Tianjin, China). CCl~4~ was obtained from Shanghai Aladdin Bio-Chem Technology Co., Ltd. (Shanghai, China). Olive oil was purchased from Shanghai Yien Chemical Technology Co., Ltd. (Shanghai, China). CCl~4~ was diluted to 40% (v/v) with olive oil before being used. The detection kits of alanine aminotransferase(ALT), aspartate aminotransferase (AST), alkaline phosphatase (ALP), and albumin (ALB) were purchased from the Nanjing Jiancheng Bioengineering Institute (Nanjing, China). Enzyme-linked immunosorbent assay(ELISA) kits for the measurement of laminin(LN), hyaluronic acid(HA), procollagen-III-peptide (PIIINP), and collagen type IV (ColIV) were offered by Shanghai Jiang Lai Biological Technology Co., Ltd. (Shanghai, China).

2.2. Animals and Experimental Design {#sec2.2}
------------------------------------

Sixty healthy male Sprague Dawley (SD) rats weighting 180-220g were purchased from the Changsha Tianqin Biotechnology Co., Ltd. (Changsha, China). All the animals were housed under the same controlled conditions with a 12 h light-dark cycle at 23±2°C temperature in the Laboratory Animal Center of Zunyi Medical University (Guizhou, China). Then, the rats were randomly divided into 6 groups with 10 rats in each group: named (I): normal control group,(II): model group, (III): positive control group (Silibinin 36mg/kg·d^−1^), (IV): DSLHG high-dose group (27g/kg·d^−1^), (V): DSLHG medium-dose group (13.5g/kg·d^−1^), (VI): DSLHG low-dose group (6.75g/kg·d^−1^). All groups were given normal water and standard rat feed. From the first day of the experiment, the abdominal cavities of other rats were injected 40% CCl~4~ with olive oil (0.2mL per 100gof bodyweight) twice a week (Tuesday and Friday) except for the normal control group, and the normal rats were handled by intraperitoneal injection with olive oil solution(2mL/kg) for seven weeks. From the 2th week, the positive control group was intragastrically administered with a dose of 10mL/kg body weight of silibinin, and the DSLHG groups were gavaged with 10mL/kg body weight of the corresponding drug concentration. In addition, the normal control group and the model group were given a gavage of distilled water of the same volume with the drug. Administration of all animals was continued for six weeks.

At the end of the eighth week, all rats were anesthetized by ether after the last gavage. Then, blood samples were collected from the rat eyelid by capillary. The whole blood was centrifuged at 3500rpm for 10min, and the upper serum was taken in a cryogenic vial and then immediately stored in a refrigerator at -20°C to test related biochemical indicators using corresponding kits. The liver tissues of the rats were removed rapidly and rinsed in pre-cold physiological saline. The right lobes of the liver (approximately 1×1×1cm^3^) were quickly fixed in 10% neutral formaldehyde solution for histopathological examination.

This protocol was approved by the Animal Care and Use Committee of the Zunyi Medical University (2019A-002) and all experimental procedures were in compliance with the National Institutes of Health Guide for Care and Use of Laboratory Animals.

2.3. Histopathological Examination {#sec2.3}
----------------------------------

The fixed liver tissues with 10% neutral buffered formaldehyde solution were dehydrated by automatic dehydrator, embedded in paraffin, and then sliced to a thickness of 4-6*μ*m sections. Hematoxylin-eosin (H&E) staining and Masson\'s trichrome staining were performed to observe the pathological and fibrosis changes, respectively. The degree of inflammation was graded based on the METAVIR scoring system: A0: no activity; A1: mild activity; A2: moderate activity; A3: severe activity. The degree of liver fibrosis was graded on a 5-point scale as either F0, F1, F2, F3, or F4, i.e., no fibrosis, portal fibrosis without septa, portal fibrosis with few septa, numerous septa without cirrhosis, and cirrhosis.

2.4. Chemical Ingredients Database Construction {#sec2.4}
-----------------------------------------------

Information of chemical compounds of each herbal medicine in DSLHG was obtained from free public database and literature. Traditional Chinese Medicine Systems Pharmacology Database and Analysis Platform \[[@B20]\](TCMSP, <http://lsp.nwu.edu.cn/tcmsp.php>), a unique system pharmacology platform designed for herbal medicines, provides a chemical screening process based on ADME features. According to the pharmacokinetic characteristics given by the TCMSP data platform, the chemical components that cannot satisfy both oral bioavailability (OB)≥30% and drug-likeness (DL) ≥0.18 are deleted \[[@B21]\]. The 2D structure of the candidate compound was searched by the PubChem database and drew with ChemBioDraw 14.0 software. Finally, the 2D structure was converted to 3D structure and saved as a MOL2 file.

2.5. Target Genes Related to the Identified Compounds {#sec2.5}
-----------------------------------------------------

The target prediction for the main active compounds was performed using the PharmMapper server\[[@B22]\] (<http://www.lilab-ecust.cn/pharmmapper/>) with the "*Homo sapiens*" species setting, which is a free public web-server that uses active small molecules as a probe to search potential drug targets. The 10 targets with the highest Fit Score were selected, and gene information including gene ID, name, and organism was identified using UniProt database(<https://www.uniprot.org/>).

2.6. Potential Target Genes for Liver Fibrosis {#sec2.6}
----------------------------------------------

The target genes associated with hepatic fibrosis were collected from the following resources: (1)GeneCards\[[@B23]\](<https://www.genecards.org/>) is a human gene database that automatically integrates data from approximately 150 web sources. We searched GeneCards database with the keywords "hepatic fibrosis" or "liver fibrosis" and found 1,222 genes related to hepatic fibrosis from the database. (2)The Online Mendelian Inheritance in Man(OMIM) database \[[@B24]\] is a continuously updated database of human genes and genetic disorders. We retrieved 50 hepatic fibrosis-related genes from the OMIM database. (3) Literature, we gathered liver fibrosis-related literature that contains 81 target genes. We finally collected a total of 1,280 genes associated with liver fibrosis through the above sources.

2.7. Construction of Network {#sec2.7}
----------------------------

In order to understand the mechanisms of DSLHG for the treatment of liver fibrosis, network analysis was performed. The corresponding network was established and visualized by Cytoscape 3.7 software. Nodes in the network represent active components and target genes. The edges indicate that the ingredients interact with the targets. The Protein-Protein Interaction (PPI) network of DSLHG on liver fibrosis was constructed using the STRING database (<https://string-db.org/>) combined with the Network Analyzer plugin of Cytoscape to filter out hub genes.

2.8. Pathway and Functional Enrichment Analysis {#sec2.8}
-----------------------------------------------

We carried out Gene Ontology (GO) function analysis and signaling pathway enrichment analysis for predicting targets of DSLHG on liver fibrosis by using DAVID bioinformatics resources 6.8 (<https://david.ncifcrf.gov/>).

2.9. Statistical Analysis {#sec2.9}
-------------------------

All experimental data were taken on the mean ± standard deviation (SD). Statistical analyses were performed with GraphPad Prism 6.0 statistical software. Rank data were analyzed with the rank sum test. A one-way analysis of variance (ANOVA) test was used to compare the mean of different groups. The data were compared by Student\'s*t*test between two groups, and*P*\<0.05 was considered as statistically significant.

3. Results {#sec3}
==========

3.1. Animal Experiments {#sec3.1}
-----------------------

The results of serum biochemical indicators in rats are shown in [Figure 2](#fig2){ref-type="fig"}. Compared with the model group, ALT, AST, HA, LN, PIIINP, and Col IV levels in rat serum were significantly reduced in DSLHG groups, as well as in the positive control group (*P*\<0.05 or*P*\<0.01).

HE and Masson staining of liver sections were shown in Supplementary [Figure 1](#supplementary-material-1){ref-type="supplementary-material"}. As shown in [Figure 3](#fig3){ref-type="fig"}, in normal control group, the hepatic lobule structure was clear, and hepatic cords were arranged radially around the central veins, and only a small amount of blue collagen fiber deposition was observed, while the liver tissue of model group indicated thickened capsule, destroyed or disappearing partial normal hepatic lobular structure, and structurally appearing "pseudolobule." Compared with model group, the histopathological examination showed that collagen deposition, liver inflammation activity, and liver fibrosis significantly reduced after treatment with DSLHG and silibinin. Additionally, no obvious pseudolobules were observed.

As shown in [Table 1](#tab1){ref-type="table"}, rank sum test showed statistical difference in the pathological and fibrosis changes between all treatment groups and the model group(*P*\<0.05). Unfortunately, none of the DSLHG groups were significantly different from the silibinin group in either of these parameters (*P*\>0.05). These results showed that DSLHG had an obvious anti-liver fibrosis effect.

3.2. Active Ingredients Filtering {#sec3.2}
---------------------------------

Total of 513 chemical constituents of seven individual herbs(Sodium Sulfate was not found in the database) in DSLHG were retrieved from TCMSP, including 61 ingredients in LH, 92 in RR, 62 in PC, 98 in GF, 17 in AF, 106 in AR, and 77 in CR. All compounds were subjected to ADME screening, and a total of 111 active compounds had OB≥30% and DL≥0.18. There are 10 compounds in LH, 16 compounds in RR, 10 compounds in PC, 15 compounds in GF, 5 compounds in AF, 6 compounds in AR, and 49 compounds in CR, respectively. Due to duplication, fifteen of these compounds were deleted, resulting in 96 effective active ingredients. In addition, among the compounds below the OB and DL screening criteria, 12(emodin, chrysophanol, physcion\[[@B25]--[@B27]\], resveratrol\[[@B28]\], polydatin\[[@B29]\], geniposide, genipin, geniposidic acid, genipin 1-gentiobioside\[[@B30]--[@B33]\], dehydrocostus lactone\[[@B34]\], neohesperidin\[[@B35]\], and tetrahydropalmatine\[[@B36]\]) were considered to be biologically active compounds, and their protective effect on liver has been reported. Therefore, the selected 108 compounds (Supplementary [Table 1](#supplementary-material-1){ref-type="supplementary-material"}) from DSLHG formula were subjected to further analysis.

3.3. Potential Targets in DSLHG {#sec3.3}
-------------------------------

Top 10 targets with the highest Fit Score were selected. Total of 192 potential targets were obtained from 108 active ingredients after removing the redundancy (Supplementary [Table 2](#supplementary-material-1){ref-type="supplementary-material"}), including MDM2, TNFBR1, MAPK14, and SRC, involved in inflammation, hepatic lipid metabolism, and the development of hepatic fibrosis. In order to make the targets more concentrated, we deleted 106 target genes which could not correspond to the disease. As shown in [Table 2](#tab2){ref-type="table"}, 86 of 192 potential targets were associated with liver fibrosis.

3.4. Compounds-Targets(C-T) Network Construction and Analysis {#sec3.4}
-------------------------------------------------------------

As shown in [Figure 4](#fig4){ref-type="fig"}, the 108 active compounds and related 192 target genes constructed the network schematic diagram. Totally, this C-T network is composed of 300 nodes (108 active compounds and 192 potential targets) and 1080 edges. In the picture, the edges indicate an association between the active ingredients and the targets. The degree values indicate the intensity of the interaction between the components and the targets. Green triangle nodes represent the active compounds of DSLHG. Circular nodes represent the potential targets of DSLHG, and the overlaps between the potential targets of the DSLHG and the liver fibrosis-related targets are indicated with pink circular nodes.

According to the network, one target gene may be complicatedly linked to multiple active ingredients of different herbs, which suggest that these compounds might synergistically contribute to the pharmacological effect of the DSLHG in the treatment of hepatic fibrosis. In addition, different active ingredients can also target the same gene, reflecting its multicomponent, multitarget, and antifibrosis effect, that was consistent with the multicomponent and multitarget characteristics of TCM.

3.5. PPI Network Construction and Analysis {#sec3.5}
------------------------------------------

86 target genes associated with active ingredients and liver fibrosis were imported into the STRING database for PPI network construction and analysis. There are 83 interacting targets in the network (HDAC8, RORA, and PDE4B are not involved in protein interaction), resulting in 594 edges representing the interaction between proteins ([Figure 5(a)](#fig5){ref-type="fig"}). Then, the PPI network was screened according to the degree values. In this work, the target genes with a degree value greater than 10 were selected as the core genes for further analysis and a total of 47 targets were screened out.

3.6. GO Functional Annotation Analysis {#sec3.6}
--------------------------------------

A total of 47 key potential genes that may be involved in liver fibrosis were uploaded to the DAVID panel for analyzing their biological process. The functional distribution of 47 targets was explored by GO functional analysis. The results of GO analysis of the predicted key targets of DSLHG acting on liver fibrosis are shown in [Figure 5(b)](#fig5){ref-type="fig"}, which listed the 20 GO terms with low*P* values and more targets enrichment. The results showed that these targets have a strong association with physiological mechanisms, such as signal transduction, protein autophosphorylation, and positive regulation of cell proliferation. These results indicated that DSLHG may play a key role in antihepatic fibrosis by manipulating these biological processes which lead to the pathogenesis of liver fibrosis.

3.7. Kyoto Encyclopedia of Genes and Genomes (KEGG) Signaling Pathway Analysis {#sec3.7}
------------------------------------------------------------------------------

To determine the relevant signaling pathways involved in the anti-liver fibrosis effect of DSLHG, we conducted pathway enrichment analysis using KEGG pathways. A total of 47 targets obtained 60 KEGG signaling pathways, and 47 channels were significantly enriched (*P*\<0.05). The senior bubble map visually showed these significantly enriched pathways ([Figure 6](#fig6){ref-type="fig"}). The color and size of the nodes in the bubble graph were decided by the number of associated genes and the*P* values. The colors from green to red reflected the*P* values from high to low, and the size of the nodes indicated how many target genes are associated. The results of KEGG pathways enrichment analysis indicated the multiple channels and mechanisms of action of DSLHG against liver fibrosis.

The top 10 pathways with lower*P*values and more genes enrichment are listed in [Table 3](#tab3){ref-type="table"}, including PI3K-Akt signaling pathway, AMPK signaling pathway, Ras signaling pathway, T cell receptor signaling pathway, PPAR signaling pathway, VEGF signaling pathway, and FoxO signaling pathway being enriched. These signaling pathways involve inflammation, metabolism, and ECM deposition. Taken together, these signaling pathways seem to be closely related to the beneficial effects of DSLHG against liver fibrosis. The illustrated network that contains main chemicals-targets-signaling pathway of DSLHG was established to understand their interaction ([Figure 7](#fig7){ref-type="fig"}).

4. Discussion {#sec4}
=============

Hepatic fibrosis is considered as the wound healing in response to the chronic liver damage caused by various factors. Excessive production and abnormal deposition of ECM are caused by the complicated interaction between various types of cells and cytokines in the liver, characterized by imbalance between the degradation and synthesis of ECM, resulting in a series of changes during the initiation and progression of liver fibrosis \[[@B3], [@B37], [@B38]\]. The occurrence of liver fibrosis is often accompanied by a certain degree of inflammatory response. Inflammation is one of the most typical features of viral, alcoholic, fatty, and autoimmune chronic liver disease. For a long time, many scholars have been working to explore the certain role of inflammation in the pathogenesis of liver fibrosis, such as the role of inflammatory mediators in the hepatic stellate cells (HSCs) activation and development of liver fibrosis \[[@B39]\]. HSCs are the main cells responsible for synthesis of ECM in normal and fibrotic liver and play central role in the development of liver fibrosis \[[@B40]--[@B42]\]. Once HSCs are activated through paracrine and autocrine routes, the imbalance between ECM synthesis and degradation was interfered, which results in aberrant accumulation of ECM in the liver \[[@B43], [@B44]\].

FoxO, a key downstream regulator in the PI3K-Akt signaling pathway belonging to subclass of the forkhead proteins family, regulates metabolic homeostasis in response to oxidative stress. Moreover, oxidative stress resistance, apoptosis, and glucose metabolism were also modulated by FoxO \[[@B45]\]. Importantly, FoxO transcription factors benefit liver fibrosis through inhibiting proliferation and transdifferentiation of HSCs \[[@B46]\].

As the downstream factor of the PI3K-Akt signaling pathway, FoxOs are controlled by Akt (protein kinase B, PKB). The PI3K/Akt signaling pathway is one of the important signaling pathways, which has increasingly raised concern under various diseases context. The PI3K-Akt signaling pathway can be activated by many types of cellular stimuli or toxic insults and regulates fundamental cellular functions, such as transcription, translation, proliferation, growth, and survival \[[@B47]\]. Some researchers \[[@B48], [@B49]\] have reported that PI3K and Akt are important in the process of the activation of hepatic stellate cells (HSCs), cell proliferation, and collagen synthesis. In contrast, PI3K and Akt are also involved in the regulation of HSCs apoptosis, which may be one of the important pathways delaying the development of liver fibrosis.

At present, most of the western medicines used for the treatment of liver fibrosis are effective only under a certain condition, with difficulty in achieving multitarget and multiechelon coverage. However, most diseases are associated with multiple targets; thus, it is difficult to achieve appropriate therapeutic results against a single target. The pharmacodynamic mechanisms of TCM against liver fibrosis have multiple levels and multiple targets and pay attention to the characteristics of overall regulation \[[@B10]\]. A new approach that analyzes TCM with network pharmacology may be a reliable way to overcome disease \[[@B51]\]. Cumulating data have shown that network pharmacology can reveal the interactions between multiple targets of compounds present in Chinese herbal medicines \[[@B52]\].

In this study, through the analysis of DSLHG compound-target-pathway network, we found that the main active components of DSLHG could act on multiple targets, indicating the multicomponent, multitarget, and overall regulation of formula. In addition, DSLHG generates the anti-liver fibrosis effect by acting on multiple pathways, multiple targets, and multiple biological processes. The predicted targets and signaling pathways in this study provide ideas for experiments to verify the key target proteins and mechanisms of antifibrosis of DSLHG in the future.

5. Conclusion {#sec5}
=============

In summary, this study used a network pharmacology approach to construct a biological network to display the interactions between compounds and protein/gene targets at a molecular or systemic level. The results indicate that DSLHG can achieve antifibrosis by acting on multiple targets and multiple pathways. Through our network analysis and prediction, the mechanisms of DSLHG formula at the molecular level are clarified, which might provide new ideas for developing new drug treatment or novel therapeutical strategies for liver fibrosis. Next, we will verify the results of network analysis prediction through manipulating the targeted molecular via pharmacological or genetical methods.
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Supplementary 1. Supplementary Table 1: the information of active compounds in DSLHG formula.*Supplementary 2.* Supplementary Table 2: the 192 potential targets of active ingredients in DSLHG formula.*Supplementary 3.*Supplementary Figure 1: HE and Masson staining of liver sections for each group.

###### 

Click here for additional data file.

![The schematic illustration of network pharmacology analysis.](ECAM2019-2630357.001){#fig1}

![Effect of DSLHG on serum biochemical levels in CCl~4~-induced liver fibrosis rats (mean ± SD). ^\#\#^*P*\<0.01, compared with the normal control group; *∗P*\<0.05, *∗∗P*\<0.01, compared with the model group; ^a^*P*\<0.05, ^b^*P*\<0.01, compared with the positive control group. I: the normal control group; II: the model group; III: the positive control group; IV: DSLHG high-dose group; V: DSLHG medium-dose group; VI: DSLHG low-dose group.](ECAM2019-2630357.002){#fig2}

![Histological results of liver tissues for each group. (a) HEstaining (×200); (b) Masson\'s trichrome staining(×200). NC: the normal control group; Model: the model group; Silibinin: the positive control group; DSLHG~H~: DSLHG high-dose group; DSLHG~M~: DSLHG medium-dose group; DSLHG~L~: DSLHG low-dose group.](ECAM2019-2630357.003){#fig3}

![Potential active compound-target network of DSLHG acting on liver fibrosis. A compound node and a target node are linked if the protein is targeted by the related compounds. Green triangle nodes represent the active compounds of DSLHG; ellipse and circular nodes are the potential targets of DSLHG; the overlap of the potential targets of the active compounds in DSLHG formula and the liver fibrosis-related targets is indicated with pink circular nodes.](ECAM2019-2630357.004){#fig4}

![The protein interaction of overlap of the potential targets of the chemical components in DSLHG with the liver fibrosis-related target genes and annotation analysis of core genes. (a) The PPI network of 86 overlap genes. (b) GO function analysis for hub genes.*Notes.* The nodes were overlap protein genes; the size of nodes from small to large represent the degree value from low to high; and these nodes color changes from green to red to indicate that the degree values change from low to high.](ECAM2019-2630357.005){#fig5}

![KEGG pathway enrichment analysis for core targets of DSLHG acting on liver fibrosis.](ECAM2019-2630357.006){#fig6}

![Main active compound(degree\>3) core target-pathway network of DSLHG on treating liver fibrosis. Core target genes are shown with blue circular nodes; green diamond nodes represent the active compounds in DSLHG formula and purple V nodes are signaling pathways.](ECAM2019-2630357.007){#fig7}

###### 

Comparison of histological activity and fibrosis stages.

  Groups      N   A   F                                 
  ----------- --- --- --- --- --------- --- --- --- --- ---------
  Normal      6   2   4   0   0         3   3   0   0   0
  Model       6   0   0   1   5^\#\#^   0   0   0   2   4^\#\#^
  Silibinin   6   0   3   3   0*∗∗*     0   1   4   1   0*∗∗*
   DSLHG~H~   6   0   2   3   1*∗∗*     0   0   4   2   0*∗∗*
   DSLHG~M~   6   0   4   2   0*∗∗*     0   2   3   1   0*∗∗*
   DSLHG~L~   6   0   2   4   0*∗∗*     0   2   4   0   0*∗∗*

A: activity grade, A0-A3; F: fibrosis stage, F0-F4. ^\#\#^*P*\<0.01, compared with the normal control group; *∗∗P*\<0.01, compared with the model group.

###### 

The overlapping targets for potential targets of the active compounds in DSLHG formula and the liver fibrosis-related targets.

  No.   Protein name                                                           Gene name   UniProt
  ----- ---------------------------------------------------------------------- ----------- ---------
  P1    Angiotensin-converting enzyme                                          ACE         P12821
  P2    Disintegrin and metalloproteinase domain-containing protein 17         ADAM17      P78536
  P3    RAC-alpha serine/threonine-protein kinase                              AKT1        P31749
  P4    Serum albumin                                                          ALB         P02768
  P5    Aldehyde dehydrogenase, mitochondrial                                  ALDH2       P05091
  P6    Angiogenin                                                             ANG         P03950
  P7    Androgen receptor                                                      AR          P10275
  P8    Aurora kinase A                                                        AURKA       O14965
  P9    Bone morphogenetic protein 2                                           BMP2        P12643
  P10   Bone morphogenetic protein 7                                           BMP7        P18075
  P11   Carbonyl reductase \[NADPH\] 1                                         CBR1        P16152
  P12   Cystathionine beta-synthase                                            CBS         P35520
  P13   Cyclin-A2                                                              CCNA2       P20248
  P14   Cyclin-dependent kinase 2                                              CDK2        P24941
  P15   Cyclin-dependent kinase 6                                              CDK6        Q00534
  P16   Cytochrome P450 2C9                                                    CYP2C9      P11712
  P17   Dipeptidyl peptidase 4                                                 DPP4        P27487
  P18   Epidermal growth factor receptor                                       EGFR        P00533
  P19   Receptor tyrosine-protein kinase erbB-4                                ERBB4       Q15303
  P20   Estrogen receptor                                                      ESR1        P03372
  P21   Prothrombin                                                            F2          P00734
  P22   Coagulation factor VII                                                 F7          P08709
  P23   Fatty acid-binding protein, adipocyte                                  FABP4       P15090
  P24   Gastrotropin                                                           FABP6       P51161
  P25   Fibroblast growth factor receptor 1                                    FGFR1       P11362
  P26   Fibroblast growth factor receptor 2                                    FGFR2       P21802
  P27   Galactokinase                                                          GALK1       P51570
  P28   Vitamin D-binding protein                                              GC          P02774
  P29   Glycogen synthase kinase-3 beta                                        GSK3B       P49841
  P30   Glutathione S-transferase A1                                           GSTA1       P08263
  P31   Glutathione S-transferase P                                            GSTP1       P09211
  P32   Tyrosine-protein kinase HCK                                            HCK         P08631
  P33   Histone deacetylase 8                                                  HDAC8       Q9BY41
  P34   Hexokinase-1                                                           HK1         P19367
  P35   Corticosteroid 11-beta-dehydrogenase isozyme 1                         HSD11B1     P28845
  P36   Estradiol 17-beta-dehydrogenase 1                                      HSD17B1     P14061
  P37   Insulin-like growth factor I                                           IGF1        P05019
  P38   Insulin-like growth factor 1 receptor                                  IGF1R       P08069
  P39   Tyrosine-protein kinase JAK2                                           JAK2        O60674
  P40   Vascular endothelial growth factor receptor 2                          KDR         P35968
  P41   Tyrosine-protein kinase Lck                                            LCK         P06239
  P42   Galectin-3                                                             LGALS3      P17931
  P43   Endoplasmic reticulum mannosyl-oligosaccharide 1,2-alpha-mannosidase   MAN1B1      Q9UKM7
  P44   Mitogen-activated protein kinase 10                                    MAPK10      P53779
  P45   Mitogen-activated protein kinase 14                                    MAPK14      Q16539
  P46   E3 ubiquitin-protein ligase Mdm2                                       MDM2        Q00987
  P47   Hepatocyte growth factor receptor                                      MET         P08581
  P48   Neprilysin                                                             MME         P08473
  P49   Macrophage metalloelastase                                             MMP12       P39900
  P50   Collagenase 3                                                          MMP13       P45452
  P51   Stromelysin-1                                                          MMP3        P08254
  P52   Neutrophil collagenase                                                 MMP8        P22894
  P53   Nitric oxide synthase, endothelial                                     NOS3        P29474
  P54   NAD(P)H dehydrogenase \[quinone\] 1                                    NQO1        P15559
  P55   Oxysterols receptor LXR-beta                                           NR1H2       P55055
  P56   Bile acid receptor                                                     NR1H4       Q96RI1
  P57   Nuclear receptor subfamily 1 group I member 2                          NR1I2       O75469
  P58   Nuclear receptor subfamily 1 group I member 3                          NR1I3       Q14994
  P59   Glucocorticoid receptor                                                NR3C1       P04150
  P60   Mineralocorticoid receptor                                             NR3C2       P08235
  P61   Ornithine carbamoyltransferase, mitochondrial                          OTC         P00480
  P62   Phenylalanine-4-hydroxylase                                            PAH         P00439
  P63   Poly \[ADP-ribose\] polymerase 1                                       PARP1       P09874
  P64   Phosphoenolpyruvate carboxykinase, cytosolic \[GTP\]                   PCK1        P35558
  P65   cAMP-specific 3′,5′-cyclic phosphodiesterase 4B                        PDE4B       Q07343
  P66   Peroxisome proliferator-activated receptor alpha                       PPARA       Q07869
  P67   Peroxisome proliferator-activated receptor delta                       PPARD       Q03181
  P68   Peroxisome proliferator-activated receptor gamma                       PPARG       P37231
  P69   Glycogen phosphorylase, liver form                                     PYGL        P06737
  P70   Retinoic acid receptor beta                                            RARB        P10826
  P71   Retinol-binding protein 4                                              RBP4        P02753
  P72   Renin                                                                  REN         P00797
  P73   GTP-binding protein Rheb                                               RHEB        Q15382
  P74   Transforming protein RhoA                                              RHOA        P61586
  P75   Nuclear receptor ROR-alpha                                             RORA        P35398
  P76   Retinoic acid receptor RXR-alpha                                       RXRA        P19793
  P77   Alpha-1-antitrypsin                                                    SERPINA1    P01009
  P78   Sex hormone-binding globulin                                           SHBG        P04278
  P79   Superoxide dismutase \[Mn\], mitochondrial                             SOD2        P04179
  P80   Proto-oncogene tyrosine-protein kinase Src                             SRC         P12931
  P81   Signal transducer and activator of transcription 1-alpha/beta          STAT1       P42224
  P82   Bile salt sulfotransferase                                             SULT2A1     Q06520
  P83   Tyrosine-protein kinase SYK                                            SYK         P43405
  P84   TGF-beta receptor type-1                                               TGFBR1      P36897
  P85   Trafficking protein particle complex subunit 3                         TRAPPC3     O43617
  P86   Transthyretin                                                          TTR         P02766

###### 

The important signaling pathways of core target genes.

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Pathway ID   Term                                Target genes                                                                                               *P*-Value
  ------------ ----------------------------------- ---------------------------------------------------------------------------------------------------------- ------------
  hsa04151     PI3K-Akt signaling pathway          AKT1, EGFR, FGFR1, FGFR2, RXRA, MET, IGF1, CDK2, KDR, PCK1, IGF1R, GSK3B, MDM2, NOS3, JAK2                 7.21E-0.9\

  hsa04068     FoxO signaling pathway              AKT1, EGFR, IGF1R, MAPK14, MDM2, IGF1, CDK2, PCK1, SOD2                                                    1.14E-06

  hsa04014     Ras signaling pathway               AKT1, EGFR, IGF1R, FGFR1, FGFR2, MET, RHOA, IGF1, KDR                                                      5.39E-05

  hsa04919     Thyroid hormone signaling pathway   AKT1, RXRA, GSK3B, ESR1, MDM2, STAT1, SRC                                                                  6.15E-05

  hsa04015     Rap1 signaling pathway              AKT1, EGFR, FGFR2, IGF1R, FGFR1, MAPK14, MET, RHOA, IGF1, SRC, KDR                                         3.55E-07

  hsa04510     Focal adhesion                      AKT1, EGFR, IGF1R, GSK3B, MET, RHOA, IGF1, SRC, KDR                                                        2.77E-05

  hsa05205     Proteoglycans in cancer             AKT1, EGFR, IGF1R, FGFR1, ERBB4, MAPK14, MET, RHOA, ESR1, MDM2, IGF1, SRC, KDR                             1.35E-09

  hsa05200     Pathways in cancer                  AKT1, EGFR, FGFR2, FGFR1, AR, BMP2, RXRA, MET, PPARG, IGF1, STAT1, CDK2, IGF1R, GSK3B, RHOA, MDM2, GSTP1   4.03E-10

  hsa05215     Prostate cancer                     AKT1, FGFR2, EGFR, IGF1R, FGFR1, AR, GSK3B, MDM2, IGF1, CDK2                                               1.91E-09

  hsa04066     HIF-1 signaling pathway             AKT1, EGFR, IGF1R, IGF1, HK1, NOS3                                                                         2.70E-04
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------

[^1]: Academic Editor: Ferdinando Nicoletti
